34 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
Migraine trials split into prevention (fewer monthly days) versus acute treatment (stopping an attack). CGRP antibodies, gepants, devices, and behavioral programs all appear on the registry. Monthly migraine-day counts are typical inclusion numbers — they come from the protocol, not from us. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (13) · Phase 3 (12) · Phase 4 (4) · Phase 2 (2) · Early phase 1 (1) · Phase 1 (1) · Phase 2 / Phase 3 (1)
This study wants to test the safety and how well it works of BHV-3000 versus dummy treatment (placebo) in the acute treatment of moderate or severe migraine in children and adolescents.
NCT04649242 · Official ClinicalTrials.gov record · Pfizer
This study wants to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
NCT04743141 · Official ClinicalTrials.gov record · Pfizer
To find out if eptinezumab is better than dummy treatment (placebo) (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
NCT04965675 · Official ClinicalTrials.gov record · H. Lundbeck A/S
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
NCT05046613 · Official ClinicalTrials.gov record · Pfizer
This study wants to compare the how well it works and safety of rimegepant to dummy treatment (placebo) as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
NCT05156398 · Official ClinicalTrials.gov record · Pfizer
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
NCT05164172 · Official ClinicalTrials.gov record · H. Lundbeck A/S
Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances.
NCT05669703 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
The goal of this watch-and-measure (no experimental treatment required) study is to learn about spatial and temporal nociceptive filtering in adolescents with chronic overlapping pain conditions (COPCs). The main questions it aims to answer are: 1.
NCT05752396 · Official ClinicalTrials.gov record · Children's Hospital Medical Center, Cincinnati
This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.
NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
NCT05897320 · Official ClinicalTrials.gov record · H. Lundbeck A/S
This study aimed to investigate the role of the glymphatic system in the initiation of migraine attacks, using non-invasive magnetic resonance imaging techniques and a validated model of migraine induction by nitroglycerin administration. Secondarily, the relationship between the function of the glymphatic system during nitroglycerin-induced migraine attacks and sleep architecture and plasma levels of migraine-involved neuropeptides will be investigated.
NCT05907655 · Official ClinicalTrials.gov record · IRCCS San Raffaele
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
NCT06810505 · Official ClinicalTrials.gov record · AbbVie
This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol.
NCT06972056 · Official ClinicalTrials.gov record · Mayo Clinic
Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and/or inflammatory diseases.
NCT07067112 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand
Rationale Understanding the mechanisms and evolution of migraine is hampered by its nature as a chronic "evolutionary" condition. Patients often come to migraine centers after years of disabling disease, non-specific diagnoses and ineffective treatments.
NCT07163416 · Official ClinicalTrials.gov record · IRCCS San Raffaele Roma
Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH.
NCT07191145 · Official ClinicalTrials.gov record · Sunnybrook Health Sciences Centre
One biopsychosocial approach proven effective in headache treatment is basic body awareness therapy. This study was planned to measure the effectiveness of basic body awareness training and lifestyle recommendations in individuals diagnosed with migraine.
NCT07328685 · Official ClinicalTrials.gov record · Mustafa Kemal University
The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress.
NCT07360405 · Official ClinicalTrials.gov record · American University
Both persistent postural-perceptual dizziness (PPPD) and vestibular migraine (VM) are common diagnoses in patients presenting to physicians for evaluation of vestibular symptoms such as dizziness and vertigo. Although they are most often described in the adult population, they are also common in children and adolescents with dizziness.
NCT07374640 · Official ClinicalTrials.gov record · Boston Children's Hospital
The ADAPT study is a single-site, Phase 2b, randomly assigned, quadruple-masked, compared with a dummy treatment trial evaluating an omega-3 dietary supplement enriched with specialized pro-resolving mediator (SPM) precursors in adults with chronic temporomandibular disorder (TMD) pain. The trial will enroll 100 adults aged 18 years or older with examiner-confirmed TMD myalgia or arthralgia will be enrolled at the University of North Carolina at Chapel Hill, Adams School of Dentistry.
NCT07437313 · Official ClinicalTrials.gov record · University of North Carolina, Chapel Hill
The goal of this study (supported by and included in the NIH HEAL Initiative: https://heal.nih.gov/) is to learn if a fully virtual study comparing two telehealth group interventions for adolescents with migraine is feasible and acceptable: 1. Telehealth group mindfulness-based intervention 2.
NCT07513662 · Official ClinicalTrials.gov record · University of Colorado, Denver
Migraine is among the leading causes of disability worldwide. Inappropriate use of acute medications in the setting of primary headache, particularly migraine can result in a debilitating condition known as medication overuse headache (MOH).
NCT07568496 · Official ClinicalTrials.gov record · Mahidol University
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack.
NCT07609914 · Official ClinicalTrials.gov record · Pfizer
This study will measure the how well it works and safety of EVO756 against dummy treatment (placebo) in adults with migraine.
NCT07616128 · Official ClinicalTrials.gov record · Evommune, Inc.
This is a neither you nor the study doctors know who gets the real treatment, randomly assigned, multicenter, outpatient evaluation of the how well it works, safety, and tolerability of elismetrep, as compared with dummy treatment (placebo), in the acute treatment of migraine.
NCT07645924 · Official ClinicalTrials.gov record · TriGemX Bio, Inc.
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a dummy treatment (placebo) (inactive treatment) at different times during the study.
NCT07646613 · Official ClinicalTrials.gov record · Aspeya, Inc.
Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days.
NCT07667621 · Official ClinicalTrials.gov record · University of South Florida
This is a long-term safety study to measure the whether it is safe and how hard side effects are to live with of intermittent use of elismetrep in the acute treatment of migraine attacks.
NCT07674654 · Official ClinicalTrials.gov record · TriGemX Bio, Inc.
This is a multicenter, single-arm, open-label Phase 4 study evaluating the whether it is safe and how hard side effects are to live with of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult patients in India who have had an insufficient response, intolerance, or contraindication to triptans. It will enroll approximately 60 participants.
NCT07685769 · Official ClinicalTrials.gov record · Pfizer
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant for the preventive treatment of chronic migraine.
NCT07729462 · Official ClinicalTrials.gov record · Pfizer
This study wants to compare the how well it works and safety of BR005-036C versus dummy treatment (placebo) in subjects with Acute Migraines
NCT07792681 · Official ClinicalTrials.gov record · Brise Pharmaceuticals Co., Ltd.
This is a neither you nor the study doctors know who gets the real treatment, randomly assigned, multicenter, outpatient evaluation of the safety and how well it works of elismetrep, as compared with dummy treatment (placebo), in the treatment of moderate or severe of migraine.
NCT07816367 · Official ClinicalTrials.gov record · TriGemX Bio, Inc.
To evaluate whether rimegepant improves acute vestibular symptoms and accompanying discomforts in patients with vestibular migraine.
NCT07871097 · Official ClinicalTrials.gov record · Wensheng Qu
People with epilepsy are predisposed to having seizures ("fits"), where abnormal electrical activity in the brain disrupts normal brain functioning. It is a common condition with around 1% of the population of Scotland having this condition.
NCT07903168 · Official ClinicalTrials.gov record · University of Aberdeen
This hub lists 34 recruiting Migraine studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “migraine” at https://clinicaltrials.gov/search?cond=migraine.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Houston, Texas; Austin, Texas; Miami, Florida; New York, New York; Dallas, Texas. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.
Amyloid and tau drugs, lifestyle trials, and studies for caregivers and prevention.
Dopamine therapies, device implants, and trials aimed at slowing progression.
B-cell drugs, remyelination experiments, and progressive-MS trials.
Drug, gene, and device studies for amyotrophic lateral sclerosis.
Add-on medicines, devices, and surgery-related studies for seizures.
Recovery, prevention after a first stroke, and acute hospital studies.